MedMira obtains NHS Supply Chain listing for Reveal Rapid HIV Test in the UK

Company's CE Approved Rapid HIV Tests Transitioned to New 3-Step Procedure and Global Reveal Brand

MedMira Inc., ("MedMira") (TSX Venture: MIR, NASDAQ: MMIRF), a developer of rapid diagnostic technology and solutions, today announced that the Company's Reveal Rapid HIV Test is now one of three rapid HIV tests listed by the National Health Services (NHS) Supply Chain in the United Kingdom, and the only one able to address both point of care and laboratory testing requirements. The NHS Supply Chain manages the procurement and delivery of healthcare products for over 600 hospitals and healthcare organizations in the UK.

"This is another step forward in our continuing sales and marketing thrust in Europe. Inclusion on the NHS list is key to accessing new opportunities to participate in healthcare tenders and provide our rapid tests to both the private and public sector healthcare organizations," said Hermes Chan, CEO, MedMira Inc. "Once again progress in developing market opportunities was achieved through our strategic partner network. Working with our partner Vitest and one of its local associates in the UK, Home Health, we were able to accelerate the introduction of Reveal into the NHS system which brings the most innovative products to healthcare providers and their patients in the UK."

Vitest AG, MedMira's strategic marketing partner for Europe and Africa, is ramping up initiatives in Europe to develop greater market penetration for the Reveal Rapid HIV Test. Supporting these efforts is CE approval of a new, easier to use, 3-step test procedure as well as the recent transition of the Company's CE-approved products to the Reveal brand, further building on the strength of this brand in the North American and international markets. Setting Reveal apart from competitors in the European market is the offer of two distinct formats, one geared for point of care testing and the other designed for laboratories and programs with batch testing requirements.

"Obtaining the NHS listing for Reveal demonstrates significant progress in our plan to build market share in the UK and other countries in Europe. As one of three listed rapid HIV tests with the NHS we are now able to bid on public tender opportunities," said Nicholas Dellaportas, Director of International Business and Sales, Vitest AG. "Building awareness of the Reveal rapid HIV test with the NHS will also benefit our marketing and business development activities in Africa as the NHS provides funding and support to many awareness campaigns where testing is a focus."